Samsung Biologics has provisionally recorded a consolidated operating profit of KRW 640.1 billion for the third quarter of this year, up 1.0% from the same period last year.

According to a regulatory filing on the 21st, Samsung Biologics' third-quarter consolidated revenue came to KRW 1.4903 trillion, up 18.5% from KRW 1.2575 trillion a year earlier and up 12.8% from the previous quarter's KRW 1.3209 trillion.

Operating profit stood at KRW 640.1 billion, up 1.0% from KRW 633.5 billion in the same period last year and up 9.1% from KRW 586.4 billion in the previous quarter.

In contrast, profit from continuing operations before corporate tax expenses fell 19.7% year-on-year and 9.0% quarter-on-quarter to KRW 532.0 billion, from KRW 662.6 billion and KRW 584.6 billion, respectively.

Third-quarter net income declined 21.2% year-on-year and 9.2% quarter-on-quarter to KRW 391.1 billion, from KRW 496.4 billion and KRW 430.7 billion, respectively. Net income attributable to owners of the parent company was also KRW 391.1 billion, recording the same rates of change.

◆ Cumulative Q1-Q3 Performance Cumulative revenue for the first three quarters of this year totaled KRW 4.0684 trillion, up 24.4% from KRW 3.2713 trillion in the same period last year. Cumulative operating profit rose 17.3% year-on-year to KRW 1.8073 trillion from KRW 1.541 trillion.

Cumulative profit from continuing operations before corporate tax expenses increased 13.8% to KRW 1.7573 trillion, while cumulative net income and net income attributable to owners of the parent company each rose 11.2% to KRW 1.291 trillion.

◆ Basis for Calculating Prior-Year Results Samsung Biologics explained in the filing that the prior-year figures are amounts from a review report that do not reflect the discontinued operations of Samsung Bioepis resulting from the horizontal spin-off. Samsung Bioepis' discontinued operations recorded a profit of KRW 78.1 billion in the third quarter of last year and KRW 113.1 billion cumulatively for the first three quarters of last year.

◆ Note on Provisional Figures The company stated that these results are provisional figures prepared before the completion of the external auditor's review and may change depending on the outcome of that review.